Glatopa is fully substitutable for 20mg branded Copaxone.
Teva’s US sales of 20mg Copaxone have been running at an annualized rate of about $1.1B.
The 20mg product has a volume share among all US Copaxone (20mg + 40mg) of about 35%, but the weekly ASP of the 20mg product is slightly higher than the 40mg product, so the dollar share of the 20mg product is slightly higher than its volume share.
Market Data 
Markets 
AI
